Pharmaceutical composition, preparation and uses thereof
The present invention relates to a pharmaceutical composition comprising the combination of (i) a biocompatible nanoparticle and of (ii) a pharmaceutical compound of interest, to be administered to a subject in need of such a compound of interest, wherein the nanoparticle potentiates the compound of interest efficiency. The longest dimension of the biocompatible nanoparticle is typically between about 4 and about 500 nm, and its absolute surface charge value is of at least 10 mV (|10 mV|). The invention also relates to such a composition for use for administering the compound of interest to a subject in need thereof, wherein the nanoparticle and the compound of interest are to be administered to said subject between more than 5 minutes and about 72 hours from each other.
1. A method for treating a cancer in a subject comprising a step of administering to the subject a pharmaceutical compound of interest and a distinct step of administering a biocompatible nanoparticle to said subject, wherein the biocompatible nanoparticle is an organic nanoparticle free of additional therapeutic, prophylactic or diagnostic agent, the longest dimension of the biocompatible nanoparticle is between about 4 nm and about 500 nm, and the surface charge value of the biocompatible nanoparticle is a negative surface charge value below −10 mV, said nanoparticle being administered to the subject between 4 hours and about 24 hours before the pharmaceutical compound of interest.
2. The method according to claim 1 , wherein the nanoparticle is selected from a lipid-based nanoparticle, a protein-based nanoparticle, a polymer-based nanoparticle, a copolymer-based nanoparticle, and a virus-like nanoparticle.
3. The method according to claim 1 , wherein the nanoparticle is further covered with a biocompatible coating.
4. The method according to claim 1 , wherein the combined administration of the biocompatible nanoparticle and the compound of interest maintains the therapeutic benefit of the compound of interest with reduced toxicity, or increases the therapeutic benefit of the compound of interest with equivalent or reduced toxicity for the subject when compared to therapeutic benefit and toxicity induced by the standard therapeutic dose of said compound of interest.
5. The method according to claim 1 , wherein the combined administration of the biocompatible nanoparticle and the compound of interest allows for a reduction of at least 10% of the administered compound therapeutic dose when compared to the standard therapeutic dose of said compound of interest while maintaining the same therapeutic benefit with equivalent or reduced toxicity for the subject, or while increasing the therapeutic benefit with equivalent or reduced toxicity for the subject.
6. The method according to claim 1 , wherein the nanoparticle is cleared from the subject to whom it has been administered within one hour and six weeks after its administration.
7. The method according to claim 1 , wherein the compound of interest is an organic compound.
8. The method according to claim 7 , wherein said organic compound is a biological compound, a small-molecule targeted therapeutic, or a cytotoxic compound.
9. The method according to claim 7 , wherein the compound of interest is selected from an antibody, an oligonucleotide, and a synthesized peptide.
10. The method according to claim 1 , wherein the compound of interest is an inorganic compound selected from a metallic nanoparticle, a metal oxide nanoparticle, a metal sulfide nanoparticle or any mixture thereof.
11. The method according to claim 1 , wherein the compound of interest is encapsulated in a carrier.
12. The method according to claim 1 , wherein the compound of interest is bound to a carrier.
13. The method according to claim 1 , wherein the nanoparticle is administered to the subject about 12 hours to about 24 hours before the pharmaceutical compound of interest.
14. The method according to claim 1 , wherein the pharmaceutical compound of interest is irinotecan.